The HER2+ subtype, derived from the amplification of the HER2 oncogene, comprises 15–20% of all BCs; the remaining 15–20% represents triple‐negative (TN) BC, which lacks ER, PR, and HER2. This evidence concerns the gene ESR1 and breast cancer.